Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Merck Capital Ventures
AddedFeb 16, 2024
UpdatedJun 28, 2026
Merck Capital Ventures

Merck Capital Ventures

Operating

Merck Capital Ventures: A US-based investment firm specializing in early to late-stage internet, pharmaceutical, and healthcare businesses.

Location
Woodcliff Lake, NJ, US
Founded
2000
Firm
Compare
Portfolio
Employees
Website

Merck Capital Ventures - Website

An index of every page on merck.com, by section.

29 pages across 7 sections · Updated Jul 14, 2026·

Homepage

Merck Capital Ventures's front door: current positioning and top-line messaging.

merck.com

TeamThomas H Glocer

Leadership and the people behind Merck Capital Ventures, as the company presents them.

  • Thomas H Glocer/leadership/thomas-h-glocer
  • Mary Ellen Coe/leadership/mary-ellen-coe
  • Pamela J Craig/leadership/pamela-j-craig
  • Stephen L Mayo Ph D/leadership/stephen-l-mayo-ph-d
  • Paul B Rothman M D/leadership/paul-b-rothman-m-d
  • Risa J Lavizzo Mourey M D

ContactContact Us

Sales, support, and partnership channels for reaching Merck Capital Ventures directly.

merck.com/contact-us

ComparisonMercks Isentress Raltegravir in Combination Therapy Demonstrated Virological and Immunological Efficacy Versus the Efavirenz Regimen at 192 Weeks of Treatment in Previously Untreated

6 comparison pages published by Merck Capital Ventures.

  • Mercks Isentress Raltegravir in Combination Therapy Demonstrated Virological and Immunological Efficacy Versus the Efavirenz Regimen at 192 Weeks of Treatment in Previously Untreated
  • Merck to Move Global Headquarters Within New Jersey
  • Merck Updates Plans for Headquarters Move in New Jersey
  • Merck Announces Positive Study Investigating the Use of Keytruda Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab Refractory Advanced Melanoma
  • New Studies Investigating the Use of Keytruda Pembrolizumab Mercks Anti Pd 1 Therapy in Advanced Melanoma Compared to Chemotherapy in Classical Hodgkin Lymphoma and in Triple Negat
  • Late Breaking Observational Data Show Patients with Type 2 Diabetes Taking Januvia Sitagliptin and Metformin Initiated Insulin Therapy at a Slower Rate Compared to Patients Taking a Sulfonylur

Products / ServicesProducts

The products and services as Merck Capital Ventures markets them.

merck.com/products
  • Safety Data Sheets/products/safety-data-sheets
  • Distributors/products/distributors

BlogMerck to Construct New Facility in the United States to Expand Manufacturing Capacity for Tice Bcg

Product updates, deep-dives, and company thinking: Merck Capital Ventures's 6-post archive.

  • Merck to Construct New Facility in the United States to Expand Manufacturing Capacity for Tice Bcg
  • Merck Statement on Ivermectin Use During the Covid 19 Pandemic
  • Merck Announces Outcome of Oncologic Drugs Advisory Committee Odac for Keytruda Pembrolizumab for Treatment of Patients with High Risk Early Stage Triple Negative Breast Cancer Tnbc
  • Merck Statement on Investigation of Pcv Presented at Advisory Committee on Immunization Practices Meeting
  • Merck Statement on Remicade and Simponi Arbitration
  • Merck Statement on Voluntary Submission of Clinical Research Protocols for Its Investigational and Approved Products

PressMedia

Official announcements and statements: 6 pages in Merck Capital Ventures's own words.

merck.com/media
  • News/media/news
  • Company Statements/media/company-statements
  • Manufacturing/media/manufacturing
  • Company Fact Sheet/media/company-fact-sheet
  • Media Library/media/media-library